ABOUT US

Interface Biologics was founded by biomaterials authority, Dr. Paul Santerre, based on his groundbreaking work at the University of Toronto on improving the biocompatibility of medical implants. Dr. Santerre investigated the effects of low molecular weight additives in polyurethanes and their ability to migrate to the nano surface, creating a non-reactive surface layer capable of bonding drug components. In the process, he also discovered that the surface chemistry of certain materials could be engineered to respond to signals from the body’s own immune system. Dr. Santerre recognized the medical and commercial impact of his discoveries.

In the December of 2001, New Generation Biotech Fund provided the initial seed capital, and Interface Biologics was born. Since that time, the company has raised $17MM in venture capital and assembled a team of scientists and experienced business executives to develop and license the company’s intellectual property.

In July 2005, Interface Biologics moved into Toronto’s acclaimed MaRS Innovation Centre---a collaborative facility dedicated to accelerating emerging technologies. Interface Biologics boasts state of the art laboratory facilities and currently employs 18 people with dedicated expertise in biochemistry, pharmacology, engineering, chemistry, microbiology, biology, process manufacturing, marketing, finance and management.

Since its time at MaRS the company has scaled the technology of its Endexo platform, increased its intellectual property estate by filing 10 new patents, and completed product prototypes for vascular access applications. The company has Master Files on record with the FDA, and has established a quality system based on ISO 13485 guidelines. Interface Biologics currently has its anti-thrombic additives manufactured in an ISO 9001 certified facility in the United States and has completed ISO 10993 biocompatibility testing on its devices containing its materials as required by US FDA.